These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 17368349)
1. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349 [TBL] [Abstract][Full Text] [Related]
2. Prevention of yellow fever in persons traveling to the tropics. Monath TP; Cetron MS Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733 [TBL] [Abstract][Full Text] [Related]
3. Review of the risks and benefits of yellow fever vaccination including some new analyses. Monath TP Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029 [TBL] [Abstract][Full Text] [Related]
4. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Staples JE; Gershman M; Fischer M; MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663 [TBL] [Abstract][Full Text] [Related]
5. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778 [TBL] [Abstract][Full Text] [Related]
6. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism. Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556 [TBL] [Abstract][Full Text] [Related]
8. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa? Baba MM; Ikusemoran M Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882 [TBL] [Abstract][Full Text] [Related]
9. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the 17D-204 yellow fever vaccine. Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Julander JG; Testori M; Cheminay C; Volkmann A Front Immunol; 2018; 9():1756. PubMed ID: 30116244 [TBL] [Abstract][Full Text] [Related]
16. Yellow fever vaccine: an effective vaccine for travelers. Verma R; Khanna P; Chawla S Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Collaborative Group for Studies with Yellow Fever Vaccine Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925 [TBL] [Abstract][Full Text] [Related]
18. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex. Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT mBio; 2019 Oct; 10(5):. PubMed ID: 31641088 [TBL] [Abstract][Full Text] [Related]
19. Yellow fever vaccines and international travelers. Barnett ED; Wilder-Smith A; Wilson ME Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013 [TBL] [Abstract][Full Text] [Related]